Hi,
I work with a drug whose antitumor mechanism of action probably involves the activation of macrophages in the tumor microenvironment. To test this hypothesis, I need to deplete the circulating monocytes in the mouse. What substance can I use?
There is a monoclonal anti-CCR2 antibody (clone MC-21) that has worked nicely for us to deplete Monocytes in T cell transfer-induced colitis (Zimmermann et al., Mucosal Immunology, 2016). Others have also used it successfully in different models such as collagen-induced arthritis (Brühl et al., Arthritis & Rheumatism, 2007) or DSS colitis (Zigmond et al., Immunity, 2012). Good luck!
Anti-CCR2 is a very popular choice, and will preferentially deplete inflammatory (Ly6C-High) monocytes. Two additional depletion options, each with their own pros cons:
- Clodronate Liposomes (intravenous injection). Effective at depletion of circulating monocytes, but will also affect other phagocytic cells in some organs. They do not cross vascular barriers easily, so generally the depletion of organ macrophages is limited to highly vascularized organs (liver, etc) and dependent on treatment dose/frequency. Investigators will sometimes compare clodronate and anti-CCR2 to test the contribution of all circulating monocytes vs. inflammatory (CCR2-Hi) monocytes.
- Anti-Ly6C/Ly6G (RB6-8C5) is also used, although it will also result in the depletion of circulating neutrophils.
The intraperitoneal injection of Marcol oil was previously reported to result in the depletion of circulating monocytes.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs